Skip to search formSkip to main contentSkip to account menu

HDM2 Antagonist JNJ-26854165

Known as: HDM2 Inhibitor JNJ-26854165 
An orally bioavailable HDM2 antagonist with potential antineoplastic activity. Hdm2 inhibitor JNJ-26854165 inhibits the binding of the HDM2 protein… 
National Institutes of Health

Related topics

Related topics

1 relation
JNJ 26854165

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
331 436 482 491 1 19 102 215 255 290 332 437 483 490 p 53 BD ACIDIC ZINC RING p 53 BD ACIDIC ZINC RING HDM 2
Súhrn Východiská: Proteíny HDM2 a HDMX sú hlavné negatívne regulátory tumorového supresoru p53. Ich úlohou je udržiavať nízku… 
2012
2012
Hdm2 Small-Molecule Inhibitors For Therapeutic Intervention In B-Cell Lymphoma
HDM2 SMALL-MOLECULE INHIBITORS FOR THERAPEUTIC INTERVENTION IN BCELL LYMPHOMA by ANGELA M. SOSIN December 2012 Advisor: Ayad M… 
2010
2010
linical Development Novel Tryptamine Derivative JNJ-26854165 Induces-Type p 53-and E 2 F 1-Mediated Apoptosis in Ther te Myeloid and Lymphoid Leukemias
ownload development of small-molecule activators of p53 is currently focused on malignancies containing a ype p53 genotype, which… 
2006
2006
Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control
The HDM2 oncoprotein is a cellular inhibitor of p53 and is frequently deregulated in human cancer. However, the HDM2 gene encodes… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)